PatientsVille.com Logo

PULMONARY EMBOLISM and Ativan

PatientsVille

PULMONARY EMBOLISM Symptoms and Causes

A pulmonary embolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung. Pulmonary embolism is a serious condition that can cause

  • Permanent damage to the affected lung
  • Low oxygen levels in your blood
  • Damage to other organs in your body from not getting enough oxygen

If a clot is large, or if there are many clots, pulmonary embolism can cause death.

Half the people who have pulmonary embolism have no symptoms. If you do have symptoms, they can include shortness of breath, chest pain or coughing up blood. Symptoms of a blood clot include warmth, swelling, pain, tenderness and redness of the leg. The goal of treatment is to break up clots and help keep other clots from forming.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for PULMONARY EMBOLISM

PULMONARY EMBOLISM treatment research studies

Ativan clinical trials, surveys and public health registries


Find Drug Side Effect reports



Ativan Side Effects

Anxiety (68)
Pain (51)
Insomnia (44)
Depression (42)
Confusional State (41)
Dyspnoea (36)
Nausea (36)
Headache (36)
Somnolence (34)
Fatigue (34)
Asthenia (32)
Feeling Abnormal (30)
Amnesia (30)
Dizziness (29)
Agitation (28)
Diarrhoea (27)
Hallucination (25)
Loss Of Consciousness (23)
Death (23)
Convulsion (22)
Aggression (22)
Fall (21)
Vomiting (21)
Overdose (21)
Tremor (20)
Pneumonia (20)
Condition Aggravated (20)
Hypotension (20)
Pulmonary Embolism (18)
Depressed Level Of Consciousness (17)
Rash (17)
Dehydration (17)
Coma (17)
Decreased Appetite (16)
Abdominal Pain (16)
Malaise (16)
Mental Status Changes (16)
Constipation (15)
Palpitations (14)
Disorientation (14)
Injury (14)
Pyrexia (13)
Nervousness (13)
Tachycardia (13)
Vision Blurred (13)
Emotional Distress (12)
Deep Vein Thrombosis (12)
Pruritus (12)
Urinary Tract Infection (12)
Pain In Extremity (12)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I was having frequent leg cramps. They worked their way from my foot up to my thigh. I just thought it was from stopping the use of muscle relaxers ( for a serious back and neck problem). I had forgotten about them and never mentioned it to either

Does valium cause afib?

I hade bacterial prostatit and i used too many antibiotik but not help but when i used alprazolam or ativan sudenly i became okai but problem is i dident find ativan in ukraine and my sister always send to me ativan frome canada some body plea

I took this for 3 weeks and by the end of my treatment I wanted to shoot everyone in my home, myself included.

I was having bad dreams and anxiety attacks (My Mom was murdered in 2005). I started drinking to calm my nerves, but decided to quit alcohol. I was told by a nurse that quiting 'Cold Turkey' could be dangerous, so I went to see th

In Oct. 2009 I went to the Emergency Room of my local hospital for a shortness of breath as I was struggling to catch my breath. I was asked if I had chest pain and responded no, just difficulty breathing. I was given morphine, pr

My email is skynet.ukr@ukr.net

My father died suddenly of a pulmonary Embolism with no signs or symtoms. We are devasted.....but the one thing that keeps pulling on my heart strings is he was already on blood thinners for years after his quadrapal by pass 13 years ago. He has been

My mother in law has been taking ativan 4 times a day , every since then she has fallen and broke her nose twice in less than four mths apart,effected her eye sight,confussion,disorented,cant remember anything are anybody. They need to take this crap

On the 12th dec2011 i nearly died from a p. e. that had been going on for some time.I had a saddle on my lungs.I was 10 days in hospital & was treated with continued oxygen,clexane injections,warfaring pills,paracetamol pills,antibiotics in

My father is suffrering from idiotypic Pulmonary Fibrosis. In medication he is taking Prednisone,Perfenodone and azathropine. he is now geeting bleeding from his nose.Can anybody inform me that this is just a side effect of any d

After a pulmunary embolism diagnosis in April 2010, I was put on Warfarin for 11 months ... I was taken off it 1 week ago... While on it I experienced extreme lethargy , difficulty concentrating, memory loss, dizziness, ongoing ch

After being discharged from eER I saw in my file that the doppler impression shows mild tricuspid regurgitation and mild pulmonary hypertension =-O scared should I be worried

Completed course of interferon and ribavirn for Hepititis C. Fell pregnant 5 months after completion of treatment and gave birth to a baby boy weighing 7.6 lbs. He has Trisomy 21. He was born with Persisitant Pulmonary hypertension and a VSD. I do no

Female 39 years old from Denmark. Was treated with Octostim as a test. After drug was administred i experience this: <span style='font-weight: bold;'><a href='http://sideeffects101.com/drug-side-effects/o/octostim-pulmonary-oedema.htm' rel='

Has any one found legal representation willing to pursue pulmonary embolis caused by avandia

Having suffered 3 dvt's, 1 pulmonary embolism, 1 stroke and 2 tis's, I was given Fragmin. I previously had been taking warfarin for about 20 yrs, this ceased to work. I am now told that I have Osteoporosis... I seem to remember along the way that

Hello, im using trabectedin in a few weeks, after using ifoosfamide+doxorrubicin to treat pulmonary methastasis or a synovial sarcoma i am concened about loosin my hair again because it means too much for a woman and is not easy to use a wig in summ

How long can one live with the diagnosis of pulmonary hypertension? I have seen 3 to 5 years but I have had it for well over 10.

Husband has been taking avodart for 3 years. Developed a tightness in lungs, dry, non-productive cough, lungs feel a burning sensation. Thorough heart echo tests done, stress test. chest x-ray, mri, blood work, pulmonary function tests all passed.

PULMONARY EMBOLISM Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)
Condition: Healthy Subjects
Interventions: Drug: Lorazepam;   Drug: Placebo
Outcome Measures: Correlated Brain Activity using MEG and SNI analysis;   Correlated Brain Activity using MEG and standard analyses
2 Unknown  Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy
Condition: Patient Satisfaction for Bronchoscopy
Interventions: Drug: Lorazepam;   Drug: Control
Outcome Measures: patient satisfaction;   relationship between patient satisfaction and sleep quality, anxiety level
3 Unknown  IM Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Agitation
Interventions: Drug: IM olanzapine;   Drug: haloperidol plus lorazepam IM
Outcome Measures: Positive and Negative Symptom Scale Excited Component (PANSS-EC);   Agitation-Calmness Evaluation Scale (ACES)
4 Recruiting Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Lorazepam;   Drug: Placebo;   Drug: Haloperidol decanoate;   Behavioral: Questionnaires
Outcome Measure: Control of Delirium Symptoms
5 Recruiting The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
Condition: Alzheimer's Disease (AD)
Intervention: Drug: lorazepam
Outcome Measures: AVLT Long term memory score;   Groton Maze Learning Test (GMLT) score
6 Recruiting Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus
Conditions: Status Epilepticus;   Epilepsy
Interventions: Drug: Clonazepam;   Drug: Fosphenytoin;   Drug: Placebo;   Drug: Lorazepam
Outcome Measures: Percentage of patient with a cessation of seizures and absence of recurrence;   Duration between the first cessation and the recurrence of seizures;   Percentage of patients having had a second injection of benzodiazepine;   Percentage of patients having had an injection of the second line treatment;   Percentage of patients having a general anesthesia for refractory status epilepticus;   Percentage of patients having had a side effect;   Percentage of patients having been mechanically ventilated;   Glasgow Coma Scale;   Mortality;   Length of stay in Intensive Care Unit;   Length of stay in hospital
7 Not yet recruiting Clobazam Use in Epilepsia Partialis Continua - Pilot Study
Conditions: Epilepsia Partialis Continua;   Kojewnikov's Epilepsy;   Epilepsy
Interventions: Drug: Clobazam;   Drug: Clonazepam;   Drug: Lorazepam
Outcome Measures: Time (measured in minutes) to onset of seizure freedom;   Reduction of seizure frequency/minute;   Mental status preservation off sedating anticonvulsants as measured by the MoCA© scale;   Ambulatory function as measured by the Hauser Ambulation Index
8 Recruiting Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly
Condition: Healthy Volunteers
Interventions: Drug: etifoxine;   Drug: lorazepam;   Drug: Placebo
Outcome Measure: Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB)
9 Recruiting Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in Elderly
Condition: Volunteers Aged Between 65 and 75 Years Old
Interventions: Drug: etifoxine;   Drug: Lorazepam;   Drug: Placebo
Outcome Measure: Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB)
10 Recruiting Characterizing and Predicting Drug Effects on Cognition
Condition: Cognitive Deficits
Interventions: Drug: Topiramate;   Drug: Lorazepam
Outcome Measures: Relationship between neurocognitive performance and study drug plasma concentration;   Neurophysiological effect of study drug on working memory
11 Recruiting Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (AATD)
Conditions: Liver Fibrosis;   Alpha-1 Antitrypsin Deficiency;   AAT Deficiency;   AATD
Interventions: Device: Abdominal ultrasound;   Procedure: History and physical;   Procedure: Intravenous catheter;   Procedure: Blood draw;   Other: Liver questionnaire;   Procedure: Liver Biopsy;   Drug: Midazolam;   Drug: Fentanyl;   Drug: Lidocaine;   Drug: Acetaminophen;   Drug: Lorazepam;   Drug: Oxycodone/Acetaminophen;   Drug: Ondansetron
Outcome Measures: To estimate the prevalence and histologic spectrum of liver injury in an adult with Alpha-1 Antitrypsin deficiency and a genotype of ZZ.;   To identify environmental and host risk factors for clinically significant liver fibrosis.;   To define the diagnostic accuracy of non-invasive markers of fibrosis in AAT liver disease.;   To explore epigenetic markers for the development of liver fibrosis.;   To quantify liver fibrosis progression.
12 Recruiting Sedative Premedication: Efficacy On Patient Experience
Condition: Perioperative Anxiety
Interventions: Drug: Lorazepam;   Other: no premedication;   Drug: Placebo (microcrystalline celluloses)
Outcome Measures: the EVAN score;   the perioperative level of anxiety
13 Not yet recruiting Explanation About Sleep in Post Trauma Patients
Conditions: Post Traumatic Stress Disorder;   Sleep Deprivation
Interventions: Behavioral: Explanation encouraging sleep;   Behavioral: Explanation discouraging sleep;   Drug: Lorazepam
Outcome Measure: PTSD severity as measured by CAPS
14 Recruiting Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability
Condition: Dental Care for Disabled
Interventions: Drug: Midazolam Mylan;   Drug: Lorazepam Mylan;   Drug: Valium + Akineton + Dehydrobenzperidol + Atropine sulfate
Outcome Measures: Level of cooperation of patient when receiving regular dental care;   Recording of vital parameters during regular dental care delivery;   Level of patient comfort and possible side-effects after dental treatment session
15 Recruiting A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865
Condition: Healthy
Interventions: Drug: PF-06372865 or Placebo;   Drug: PF-06372865 or Placebo or Lorazepam
Outcome Measures: Maximum Observed Plasma Concentration (Cmax);   Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Area Under the Curve From Time Zero to Extrapolated Infinite Time;   Apparent Oral Clearance (CL/F);   Apparent Volume of Distribution (Vz/F);   Plasma Decay Half-Life (t1/2);   Area Under the Curve From Time Zero to 24 hours;   Change in Saccadic Eye Movements (saccadic reaction time, saccadic peak velocity and saccadic inaccuracy);   Change in Body Sway;   Change in Smooth Pursuit;   Change in Bond and Lader VAS;   Change in Adaptive Tracking;   Change in Visual Verbal Learning Test;   Change in Pharmaco-EEG
16 Unknown  Enteral Versus Intravenous Sedation in Critically Ill High-risk ICU Patients
Conditions: Critical Illness;   Mechanical Ventilation Complication
Interventions: Procedure: Enteral Sedation (EN);   Procedure: Control group: Intravenous Sedation (IV)
Outcome Measures: Percent of efficacy, measured by observed RASS = desired RASS ± 1.;   Sedation protocol effectiveness: percentage of "protocol violation days" on the total of ICU days.;   Delirium and coma free days (respectively negative CAM-ICU and RASS > - 3 in all daily observations until 28° ICU day) (11);   Ventilation free days (12);   Nursing evaluation of sedation adequacy (communication skills, cooperation, environment tolerance) (13);   Overall ICU and hospital mortality, absolute mortality after 1 year from ICU discharge.;   Sedative drugs costs.;   Indirect inefficacy markers
17 Recruiting Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Conditions: Alcohol Withdrawal Delirium;   Alcohol Withdrawal Associated Autonomic Hyperactivity;   Alcohol Withdrawal Hallucinosis;   Alcohol Withdrawal-Induced Delirium Tremens
Interventions: Drug: Dexmedetomidine;   Drug: Placebo
Outcome Measures: The length of ICU stay defined as the time between randomization and ICU transfer orders.;   The number of delirium-free and ventilator-free days during the first 28 days of hospitalization;   The length in days of the hospital stay;   Scores at hospital discharge on the Mini Mental Exam, Beck Depression Inventory, Beck Anxiety Inventory and PTSD checklist.;   Resource utilization costs associated with this hospitalization.;   Predefined adverse events;   average MINDS score
18 Unknown  Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression
Condition: Depression
Interventions: Device: Thrymatron System IV device (CONSOLIDATION ELECTROCONVUsLIVE THERAPY) plus PHARMACOTHERAPY;   Drug: PHARMACOTHERAPY
Outcome Measures: Hamilton Depression Rating Scale 21 items (HDRS-21);   Mini-Mental State Examination (MMSE 35);   UKU - Adverse effects rating scales;   Demographical Data Memory (MEDABI-20);   Rey Figure;   Trail Making Test A;   Trail Making Test B;   Stroop Test;   Direct and inverse digits (WAIS, Weschler Adults Intelligence Sacle).;   Vocabulary WAIS (Weschler Adults Intelligence Scale);   Frequency Hospitalization Quotient;   Hospital Day Quotient (HDQ)
19 Not yet recruiting Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Standard anti-emetics in conjunction with R-CHOP
Outcome Measures: Complete Response, Acute Phase (Day 1), Cycle 1;   Complete Response, Delayed Phase (Days 2 to 11), Cycle 1;   Complete Response - Cycle 2 and beyond;   No Significant Nausea - Cycle 2 and beyond;   Failure of standard anti-emetic prophylaxis, Day 1 to Day 11, Cycle 1 and beyond;   Frequency of common adverse events associated with anti-emetics;   Severity of common adverse events associated with anti-emetics
20 Recruiting TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation
Conditions: Cardiac Arrest;   Postanoxic Encephalopathy;   Status Epilepticus
Interventions: Drug: Anti-epileptic drugs;   Other: No anti-epileptic drugs
Outcome Measures: Neurological outcome;   Long term outcome